On January 5, 2026, Daniel Markowitz of Evercore ISI Group issued an “In-Line” rating for Bio-Techne Corporation (TECH), placing a price target of $68 on the stock. This comes as a key moment for investors looking to evaluate the company’s potential given its current trading price of $63.03. With a slight upside projected, this rating offers a balanced perspective amid fluctuating market conditions.
Recent Price Action
Bio-Techne’s stock has seen notable activity in recent sessions, closing at $63.03, reflecting a daily change of $3.38, or 5.67%. This uptick is particularly significant given its position within a broader range—its 52-week high stands 20.5% below this mark, indicating some volatility in price action over the past year. The stock has experienced a 52-week low of $36.99, and the fluctuation is echoed in its volatility metrics; the stock’s beta stands at 1.469. Trade volumes have also seen an uptick, with approximately 2,071,854 shares exchanging hands, surpassing the average volume of 1,837,087 shares. This surge reflects heightened investor interest in Bio-Techne, possibly driven by its recent performance and outlook.
Historical Performance
In terms of historical performance, Bio-Techne has shown modest returns. Over the past 30 days, the stock has gained 0.13%, while its quarterly performance has been slightly better at 1.51%. However, in the context of broader market conditions, these gains appear tame. The stock’s weekly volatility is recorded at 1.68%, with a monthly volatility reaching 2.85%. An average trading volume of 1,237,553 shares over the last ten days suggests that while trading activity is robust, it hasn’t translated into substantial price movements compared to its overall market environment.
Earnings Analysis
The most recent earnings announcement is a crucial determinant of Bio-Techne’s valuation trajectory. For the quarter ending November 5, 2025, the company reported an earnings per share (EPS) of $0.2442, significantly missing the estimate of $0.42 by 41.86%. This marks a stark difference from its previous earnings report from August 6, 2025, which surprised against expectations with an actual EPS of $0.53 compared to an estimate of $0.50. The recent underperformance may raise questions regarding the company’s earnings predictability and operational efficiency, a point worth monitoring for potential investors.
Analyst / Consensus View
Sentiment towards Bio-Techne appears generally favorable despite the recent earnings miss. Within the last 90 days, the stock has received five ratings: four “Buy” ratings and one “Hold,” with no sell ratings issued. The average price target stands at $69.2, with a high estimate of $70. Notably, the recent analyst rating from Evercore ISI Group positions the stock clearly within the “In-Line” category, suggesting that while the upside is limited in the near term, there remains some belief in its growth potential.
Stock Grading or Fundamental View
Bio-Techne currently holds a Stocks Telegraph (ST) Score of 46, indicating a mixed assessment of its financial health and investment attractiveness. This score reflects various underlying factors, ranging from its revenue generation capabilities to investor sentiment and market positioning. A score of this magnitude suggests the company has room for improvement, particularly in stabilizing its earnings and responding effectively to market challenges.
Conclusion
For investors considering Bio-Techne Corporation, this stock may be best suited for those with a moderate risk tolerance and a focus on mid-term growth prospects. While the company’s recent earnings undershoot raises caution, the favorable analyst sentiment coupled with solid historical stock performance presents a balanced opportunity. Potential investors should also be mindful of the inherent risks, particularly around earnings predictability and external market pressures. Given its mix of performance metrics and ratings, Bio-Techne is worth monitoring as it navigates the current landscape, especially for those seeking a moderate, growth-oriented addition to their portfolio.